This company has shut down. ACELYRIN is no longer operating — its last tracked round was a Series C in 2022.
Explore the Startup GraveyardACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
ACELYRIN has raised $300.0M in total funding. The most recent round was Series C. The last funding was announced in September 2022.
ACELYRIN's investors include Samsara BioCapital, OrbiMed, RTW Investments, Westlake Village BioPartners, Decheng Capital.
ACELYRIN is headquartered in Los Angeles, United States.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
ACELYRIN is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ACELYRIN — Funding & Investors." VCBacked, September 13, 2022, https://www.vcbacked.co/company/acelyrin. Accessed August 13, 2026.
VCBacked. (2022). ACELYRIN — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/acelyrin
{{cite web |title=ACELYRIN — Funding & Investors |url=https://www.vcbacked.co/company/acelyrin |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated